CHRU Dijon

Dijon 21000

0 studies enrolling now · 1 studies all time

What they study most

Advanced Cholangiocarcinoma, FGFR2 Gene Mutation

Studies at this site

• Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations — Stopped early